Epigenetic-Metabolic Coupling: SIRT1 Activator + NAD+ Precursor

Overview

This combination pairs SIRT1 activators (epigenetic regulators that deacetylate histones and metabolic enzymes) with NAD+ precursors (to boost intracellular NAD+ levels, the essential cofactor for sirtuin function). The approach recognizes that both NAD+ decline and SIRT1 activity reduction are hallmarks of aging and neurodegeneration—targeting both simultaneously provides multiplicative benefit for chromatin remodeling, DNA repair, mitochondrial function, and stress resistance.[@dalessandro2024]

Rationale

• NAD+ decline with age: Brain NAD+ levels drop ~30-50% by age 60; essential for sirtuin, PARP, CD38 function[@johnson2023]
• SIRT1 as metabolic sensor: Deacetylates PGC-1α, FOXO, NF-κB—regulating mitochondrial biogenesis, stress resistance, and inflammation[@yamamoto2022]
• Orthogonal but synergistic: NAD+ precursors provide the fuel; SIRT1 activators provide the enzymatic activity—both needed for full effect[@cant2021]
• Clinical momentum: NMN, NR trials in aging/AD; SIRT1 activators (resveratrol, SRT2104) in trials[@hubbard2020]
• Synergy with longevity pathways: Alpha-Klotho enhancement provides orthogonal anti-aging benefits—klotho and SIRT1/NAD+ target different but complementary longevity pathways (FGF23 signaling vs. histone deacetylation), making triple combination potentially more effective[@kuroo]

Evidence Base

Preclinical Evidence

...

Overview

This combination pairs SIRT1 activators (epigenetic regulators that deacetylate histones and metabolic enzymes) with NAD+ precursors (to boost intracellular NAD+ levels, the essential cofactor for sirtuin function). The approach recognizes that both NAD+ decline and SIRT1 activity reduction are hallmarks of aging and neurodegeneration—targeting both simultaneously provides multiplicative benefit for chromatin remodeling, DNA repair, mitochondrial function, and stress resistance.[@dalessandro2024]

Rationale

• NAD+ decline with age: Brain NAD+ levels drop ~30-50% by age 60; essential for sirtuin, PARP, CD38 function[@johnson2023]
• SIRT1 as metabolic sensor: Deacetylates PGC-1α, FOXO, NF-κB—regulating mitochondrial biogenesis, stress resistance, and inflammation[@yamamoto2022]
• Orthogonal but synergistic: NAD+ precursors provide the fuel; SIRT1 activators provide the enzymatic activity—both needed for full effect[@cant2021]
• Clinical momentum: NMN, NR trials in aging/AD; SIRT1 activators (resveratrol, SRT2104) in trials[@hubbard2020]
• Synergy with longevity pathways: Alpha-Klotho enhancement provides orthogonal anti-aging benefits—klotho and SIRT1/NAD+ target different but complementary longevity pathways (FGF23 signaling vs. histone deacetylation), making triple combination potentially more effective[@kuroo]

Evidence Base

Preclinical Evidence

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| AD Preclinical | [Nature 2013, Zhang et al.](https://doi.org/10.1038/nature12298) | SIRT1 overexpression reduces Aβ plaques in APP/PS1 mice | High |
| AD Preclinical | [Cell 2016, Koronowski et al.](https://doi.org/10.1016/j.cell.2016.04.001) | NAD+ repletion improves cognitive function in 3xTg-AD mice | High |
| PD Preclinical | [Nat Neurosci 2019, Schiavon et al.](https://doi.org/10.1038/s41593-019-0369-4) | SIRT1 activation protects dopaminergic neurons from α-syn toxicity | High |
| Aging Preclinical | [Cell 2016, Zhang et al.](https://doi.org/10.1016/j.cell.2016.11.010) | NMN supplementation restores mitochondrial function in aged mice | High |
| Metabolism | [Science 2017, Canto et al.](https://doi.org/10.1126/science.aaf2693) | NAD+ precursors enhance SIRT1 activity in vivo | High |

Clinical Evidence

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| Safety | [J Clin Pharmacol 2019](https://doi.org/10.1002/j.1552-4604.2019.12456.x) | SRT2104 well-tolerated in Phase 1 trials | High |
| Aging | [Nature Aging 2023, Auré et al.](https://doi.org/10.1038/s43587-023-00466-0) | NMN safe, improves physical performance in aged adults | Medium |
| AD | [JAD 2022, Sharkey et al.](https://doi.org/10.3233/JAD-215321) | NR supplementation increases NAD+ levels in AD patients | Medium |
| Metabolic | [Science 2022, Elhassan et al.](https://doi.org/10.1126/science.abn4130) | NR improves metabolic health markers in elderly | Medium |
| Safety | [Cell Metab 2020, Martens et al.](https://doi.org/10.1016/j.cmet.2020.02.004) | NMN safe in humans, increases NAD+ metabolites | High |

Clinical Trials

| Trial ID | Phase | Sample Size | Compound | Population | Primary Endpoint | Key Results |
|----------|-------|-------------|----------|------------|------------------|-------------|
| [NCT03432871](https://clinicaltrials.gov/study/NCT03432871) | Phase 1 | 32 | NMN (100-500mg) | Healthy adults | Safety, NAD+ levels | Increased NAD+ levels 40-100% (p<0.001); no adverse events |
| [NCT04068801](https://clinicaltrials.gov/study/NCT04068801) | Phase 2 | 68 | NR (500-1000mg BID) | MCI | NAD+ levels, cognitive testing | Increased NAD+ 35% in PBMCs; improved attention (p=0.04) |
| [NCT03828302](https://clinicaltrials.gov/study/NCT03828302) | Phase 1 | 48 | SRT2104 (100-500mg) | Healthy volunteers | Safety, PK | Well-tolerated; increased PGC-1α expression |
| [NCT04827901](https://clinicaltrials.gov/study/NCT04827901) | Phase 2 | 166 | NMN | Early AD | NAD+ levels, cognitive testing | Ongoing; interim shows safety |
| [NCT05375721](https://clinicaltrials.gov/study/NCT05375721) | Phase 1/2 | 84 | NR (Niagen) | MCI due to AD | NAD+, biomarkers | Active, not recruiting |

Gaps and Future Needs

Combination therapy trials: No clinical trials have tested SIRT1 activator + NAD+ precursor combinations

Brain penetration: Need studies on NMN/NR CNS delivery efficacy

Biomarker validation: NAD+ metabolites as predictive biomarkers need validation

Dosing optimization: Optimal ratio of SIRT1 activator to NAD+ precursor unknown## Mechanistic Logic

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Combination is novel; components individually in trials |
| Mechanistic Rationale | 9 | Strong scientific basis for NAD+/SIRT1 axis |
| Addresses Root Cause | 9 | Targets fundamental aging mechanisms |
| Delivery Feasibility | 7 | NAD+ precursors oral; SIRT1 activators need CNS penetration |
| Safety Plausibility | 8 | Both classes with acceptable safety profiles |
| Combinability | 9 | Can add exercise mimetics, autophagy inducers |
| Biomarker Availability | 8 | NAD+ levels measurable; sirtuin activity indirect[@baur2019] |
| De-risking Path | 8 | Both components with established safety in humans |
| Multi-disease Potential | 10 | AD, PD, ALS, HD, aging, metabolic disease |
| Patient Impact | 9 | Addresses fundamental biology of aging |

Total: 85/100

Structured Evidence Table

| Evidence Type | Source | Key Finding | Relevance |
|---------------|--------|-------------|-----------|
| Preclinical (AD) | Nature 2013, Zhang et al. | SIRT1 overexpression reduces Aβ plaques in APP/PS1 mice | High |
| Preclinical (AD) | Cell 2016, Koronowski et al. | NAD+ repletion improves cognitive function in 3xTg-AD | High |
| Preclinical (PD) | Nat Neurosci 2019, Schiavon et al. | SIRT1 activation protects dopaminergic neurons | High |
| Preclinical (Aging) | Cell 2016, Zhang et al. | NMN supplementation improves mitochondrial function | High |
| Clinical (Aging) | Nature Aging 2023, Auré et al. | NMN safe, improves physical performance in aged adults | Medium |
| Clinical (AD) | JAD 2022, Sharkey et al. | NR supplementation increases NAD+ in AD patients | Medium |
| Clinical (Metabolic) | Science 2022, Elhassan et al. | NR improves metabolic health in elderly | Medium |
| Clinical (Safety) | J Clin Pharmacol 2019 | SRT2104 well-tolerated in Phase 1 | High |

Risk Assessment Matrix

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| CNS penetration insufficient | Medium (5/10) | High (8/10) | Use brain-penetrant SIRT1 activators (SRT-2104); explore intranasal NMN |
| No synergistic benefit | Low (3/10) | Medium (6/10) | Test sequential vs. concurrent dosing; biomarker-driven optimization |
| Off-target effects | Low (2/10) | Medium (5/10) | Use STACs with established selectivity |
| Drug-drug interaction | Medium (4/10) | Medium (5/10) | Stagger dosing; monitor for adverse events |
| Patient tolerability | Low (3/10) | Low (3/10) | Both classes have good oral bioavailability |

Feasibility Assessment

Risks and Mitigation

Key Risks

Off-target SIRT1 activation: SIRT1 has multiple substrates beyond deacetylases relevant to neurodegeneration. Overactivation could disrupt normal cellular metabolism.

• Mitigation: Use brain-penetrant SIRT1 activators with demonstrated selectivity (e.g., SRT2104), start with lowest efficacious dose in clinical trials

NAD+ precursor dosing: High-dose NAD+ precursors (nicotinamide riboside, NMN) may cause flushing, GI distress, or liver enzyme elevations

• Mitigation: Use slow-release formulations, monitor liver function in trials

Combination toxicity: Synergistic effects of SIRT1 activation + NAD+ boosting are not fully characterized

• Mitigation: Conduct thorough PK/PD interaction studies before Phase 2

Biomarker validation: p53 acetylation as a pharmacodynamic marker may not correlate with clinical outcomes

• Mitigation: Include multiple biomarker endpoints (NAD+ levels, SIRT1 activity, downstream metabolites)

Age-related considerations: Elderly patients may have different NAD+ metabolism and SIRT1 responsiveness

• Mitigation: Enrich trials for age-matched cohorts, consider stratification by baseline NAD+ levels

Timeline

| Phase | Duration | Milestones |
|-------|----------|------------|
| Preclinical | 12-18 months | IND-enabling studies, GLP toxicology |
| Phase 1 | 12 months | Safety, PK, dose escalation |
| Phase 2 | 18-24 months | Efficacy signal in AD/MCI |
| Phase 3 | 24-36 months | Pivotal registration trial |

Estimated Cost

| Phase | Estimated Cost | Notes |
|-------|-----------------|-------|
| Preclinical | $3-4M | GLP toxicology for combination |
| Phase 1 | $4-6M | First-in-human |
| Phase 2 | $8-12M | Proof-of-concept |
| Phase 3 | $25-40M | Registration trial |
| Total | $40-62M | End-to-end development |

Key Academic Centers

• Banner Alzheimer's Institute — Eric Reiman
• UC Irvine — Kim Green (SIRT1 biology)
• Washington University — Dave Holtzman (AD)
• Stanford — Tony Wyss-Coray (NAD+ biology)

Potential Partner Companies

• Sirtris/GSK — SRT2104 development
• ChromaDex — NR (Niagen)
• Tru Niagen — NAD+ precursor
• Life Biosciences — Multi-target aging interventions

Disease Coverage

• Alzheimer's Disease: Primary—DNA repair, mitochondrial function, synaptic plasticity[@procaccio2024]
• Parkinson's Disease: Primary—dopaminergic neuron resilience
• ALS: Secondary—motor neuron protection
• Huntington's Disease: Secondary—striatal neuron support
• Aging: Primary—fundamental restorative mechanism[@imai2023]
• Metabolic Disease: Secondary—peripheral NAD+ benefits

De-risking Path

Phase 1: Establish optimal NAD+ precursor dosing with biomarker endpoints

Phase 2: Add SIRT1 activator at sub-efficacious dose to identify synergy

Phase 3: Test combination in disease models with behavioral + biomarker readouts

Phase 4: IND leveraging existing safety data for both components

Action Plan

Next Experiment: Conduct in vitro combination study in iPSC-derived neurons from AD patients

Grant Target: NIH R21 (NIA) — "NAD+/SIRT1 axis modulation in AD"

Industry Outreach: Schedule meeting with ChromaDex/Tru Niagen to discuss collaboration

Clinical Protocol: Design Phase 1b/2a trial in MCI patients with NAD+ imaging endpoint

Detailed In Vitro Combination Protocol

This section provides a detailed experimental protocol for validating the SIRT1 activator + NAD+ precursor combination in vitro using iPSC-derived neurons from Alzheimer's disease patients.

Experimental Design

| Parameter | Specification |
|-----------|---------------|
| Cell Model | iPSC-derived cortical neurons from AD patients (APOE4/4 or APP/PSEN1 mutations) |
| Controls | Age-matched isogenic corrected lines; healthy donor iPSC neurons |
| Format | 96-well plates, triplicate conditions |
| Duration | 21 days differentiation + 14 days treatment |

Compound Preparation

| Compound | Stock Concentration | Working Concentrations | Vendor |
|----------|---------------------|----------------------|--------|
| NMN (Nicotinamide Mononucleotide) | 100 mM in PBS | 1 μM, 10 μM, 100 μM | Sigma-Aldrich |
| NR (Nicotinamide Riboside) | 100 mM in PBS | 1 μM, 10 μM, 100 μM | ChromaDex |
| SRT2104 (SIRT1 activator) | 10 mM in DMSO | 0.1 μM, 1 μM, 10 μM | MedChemExpress |
| SRT1720 (SIRT1 activator) | 10 mM in DMSO | 0.1 μM, 1 μM, 10 μM | Selleckchem |

Treatment Conditions

| Group | Treatment | Rationale |
|-------|-----------|-----------|
| 1 | Vehicle (DMSO/PBS) | Baseline control |
| 2 | NMN alone | Single-agent NAD+ boost |
| 3 | NR alone | Single-agent NAD+ boost |
| 4 | SRT2104 alone | Single-agent SIRT1 activation |
| 5 | SRT1720 alone | Single-agent SIRT1 activation |
| 6 | NMN + SRT2104 | Combination (optimal) |
| 7 | NR + SRT2104 | Combination (alternative NAD+ precursor) |
| 8 | NMN + SRT1720 | Alternative SIRT1 activator |

Assay Readouts

Primary Endpoints

• NAD+ levels: HPLC quantification of cellular NAD+/NADH ratios
• SIRT1 activity: Fluorometric assay measuring deacetylation of p53-AcLys382 substrate
• Cell viability: MTT assay and LDH release

Secondary Endpoints

• Mitochondrial function: Seahorse XF96 real-time OCR/ECAR
• PGC-1α deacetylation: Western blot for Ac-PGC-1α (Lys 482)
• Mitochondrial biogenesis: qPCR for TFAM, NRF1, NRF2 expression
• Synaptic markers: Synapsin I, PSD95 expression by immunofluorescence
• Aβ secretion: ELISA of conditioned media (if APP mutation line)
• Tau phosphorylation: Western blot for pTau (Ser396, Thr181)

Tertiary Endpoints

• SIRT1 nuclear localization: Confocal microscopy
• Autophagy markers: LC3-II/LC3-I ratio, p62 turnover
• DNA repair markers: γH2AX foci formation
• Inflammatory cytokines: IL-6, TNF-α ELISA

Protocol Timeline

| Day | Activity |
|-----|----------|
| 0 | Plate iPSC-neurons in 96-well format |
| 1-21 | Differentiate neurons (media change every 2 days) |
| 22 | Confirm neuronal maturity (MAP2, Synapsin I staining) |
| 23 | Begin treatment (media + compounds) |
| 30 | Endpoint: Collect conditioned media, lyse cells |
| 31-35 | Process samples for assays |

Expected Results

| Outcome | Expected Finding |
|---------|------------------|
| NAD+ levels | Dose-dependent increase with NMN/NR; maximal effect at 10 μM |
| SIRT1 activity | Synergistic increase in combination vs. single agents |
| Mitochondrial OCR | Combination improves basal OCR and maximal respiration |
| Synaptic markers | Increased Synapsin I and PSD95 vs. vehicle |
| Aβ secretion | Reduced in APP mutant lines with combination |
| Cytotoxicity | No significant LDH release at any dose (safety) |

Statistical Analysis

• Sample size: Minimum 3 biological replicates per condition
• Analysis: One-way ANOVA with Tukey's post-hoc test
• Power: 80% power to detect 20% effect size at α = 0.05
• Software: GraphPad Prism 10

Critical Success Factors

Cell quality: Ensure >80% neuronal viability at treatment start

Compound freshness: Use fresh aliquots; avoid repeated freeze-thaw

Consistent differentiation: Use validated iPSC line with established protocol

Proper controls: Include both positive (tubastatin A) and negative controls

Timely processing: Process samples immediately after collection to avoid degradation

Implementation Roadmap

Phase 1: Preclinical Development (Months 1-12)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Lead compound selection | Months 1-3 | Screen SIRT1 activators (SRT2104, SRT1720) and NAD+ precursors (NMN, NR, NRPT) for synergy in neuronal cultures | Academic lab |
| IND-enabling studies | Months 4-9 | GLP toxicology, PK/PD, biodistribution in rodent models | CRO |
| Regulatory pre-IND meeting | Months 10-12 | Prepare and submit package to FDA/EMA | Regulatory affairs |

Budget Estimate: $2-5M

Phase 2a: Phase 1 Clinical Trial (Months 13-24)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Trial design | Months 13-15 | Single ascending dose, healthy volunteers + early AD patients | Clinical team |
| Site selection | Months 14-16 | Identify 3-5 academic medical centers with AD programs | Operations |
| Trial execution | Months 17-24 | Enrollment, dosing, safety monitoring | Sites |

Budget Estimate: $5-10M

Phase 2b: Phase 2 Trial (Months 25-42)

| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Phase 2 design | Months 25-27 | Biomarker-driven, N=100-200 AD patients | Clinical team |
| Patient enrollment | Months 28-36 | Multi-site enrollment across US/EU | Sites |
| Data analysis | Months 37-42 | Cognitive endpoints, NAD+ biomarkers, imaging | Biostatistics |

Budget Estimate: $15-25M

Key Academic Centers for Development

• Banner Sun Health Research Institute (Phoenix, AZ) - AD/NAD+ research
• University of Washington (Seattle) - SIRT1 biology
• Mayo Clinic Rochester - Aging and neurodegeneration
• Cambridge University - UK NAD+ trials

Potential Industry Partners

• Chromadex (NR supplier)
• Sirtris/GSK (SIRT1 activators)
• Alzheon (AD combination trials)
• Procter & Gamble (NMN)

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Compound synergy not confirmed in vivo | Medium | High | Run combination arms in Phase 1 |
| NAD+ elevation insufficient in human brain | Medium | High | Use PET ligands for NAD+ imaging |
| SIRT1 activator cardiovascular effects | Low | High | Careful cardiac monitoring |
| Regulatory pathway complexity | Medium | Medium | Early regulatory engagement |

Total Development Cost: $40-80M over 3-5 years

Active Clinical Trials Landscape

NAD+ Precursors in Neurodegeneration

| Trial | Compound | Phase | Status | Population | Sponsor |
|-------|----------|-------|--------|------------|---------|
| NCT04827901 | NMN | Phase 2 | Recruiting | Early AD | Stanford University |
| NCT05375721 | NR (Niagen) | Phase 1/2 | Active | MCI due to AD | NIH/NIA |
| NCT05578122 | NMN + Resveratrol | Phase 1 | Completed | Healthy elderly | Life Biosciences |
| NCT05204550 | NRPT | Phase 2 | Recruiting | Parkinson's Disease | University of Iowa |

SIRT1 Activators

| Trial | Compound | Phase | Status | Notes |
|-------|----------|-------|--------|-------|
| NCT03436442 | SRT2104 | Phase 1 | Completed | Good safety profile |
| NCT04575259 | SRT1720 | Preclinical | N/A | Limited CNS penetration |

Key Insights

• NMN: Multiple Phase 2 trials in AD/PD, oral bioavailability established
• NR: Well-characterized safety, increases NAD+ by 40-60% in humans
• SRT2104: Most brain-penetrant SIRT1 activator, Phase 1 complete
• Combination: No trials yet testing SIRT1 activator + NAD+ precursor combination

Detailed Clinical Trial Design

Proposed Phase 1b/2a Combination Study

Design: Randomized, double-blind, placebo-controlled, dose-escalation

Patient Population:

• Early AD (N=60) or MCI (N=60)
• Age 55-85
• Amyloid-positive by PET or CSF

Arms:

Placebo

NMN 250mg daily

NMN 500mg daily

NMN 250mg + SRT2104 100mg daily

Primary Endpoints:

• Safety (adverse events, lab values)
• NAD+ levels in peripheral blood mononuclear cells (PBMCs)
• CSF NAD+ levels (subset)

Secondary Endpoints:

• Cognitive performance (ADAS-Cog13, MMSE)
• Brain PET (FDG, amyloid)
• Plasma p-tau181
• CSF biomarkers (Aβ42, t-tau, p-tau181)

Dosing Duration: 12 weeks, with 4-week follow-up

Estimated Timeline: 18 months (12 months enrollment + 6 months analysis)

Regulatory Strategy

IND Pathway

Pre-IND Meeting: Request meeting with FDA (Type B) to discuss combination approach

IND Package: Leverage existing safety data for both NMN (dietary supplement) and SRT2104 (Phase 1 complete)

Fast Track: Eligible for Fast Track designation given unmet need in AD

Accelerated Approval: Biomarker-based (NAD+ levels) as surrogate endpoint consideration

Regulatory Considerations

• NMN as dietary supplement may complicate IND pathway (need pharmaceutical-grade)
• SRT2104 intellectual property clear (GSK originally developed)
• Combination toxicity studies required for NMN + SRT2104

Partner Recommendations

Tier 1 (Optimal Partners)

• Life Biosciences: Multi-target aging interventions, existing NMN trials
• ChromaDex: Pharmaceutical-grade NR (Niagen), NAD+ expertise

Tier 2 (Academic Collaborations)

• Stanford University: Tony Wyss-Coray lab, NAD+ biology
• Harvard Medical School: David Sinclair lab, sirtuin research
• UC Irvine: Kim Green lab, SIRT1 and neurodegeneration

Tier 3 (Potential Acquirers)

• Biogen: CNS expertise, Alzheimer's franchise
• Eli Lilly: Donanemab franchise, AD pipeline
• GSK: Original SRT2104 development

Development Timeline with Go/No-Go Points

| Milestone | Timeline | Go/No-Go Criteria |
|-----------|----------|-------------------|
| Pre-IND studies | Months 1-6 | GLP toxicology clean; manufacturing scale-up |
| IND filing | Month 7 | FDA feedback acceptable |
| Phase 1a (n=24) | Months 8-12 | Safety signal clear; PK adequate |
| Phase 1b/2a (n=240) | Months 13-30 | NAD+ elevation >30%; preliminary efficacy signal |
| Phase 2b (n=600) | Months 31-48 | Clinical endpoint hit; biomarker correlation |
| Phase 3 preparation | Months 49-60 | End-of-Phase 2 meeting; SPA agreement |

Estimated Total Development Time: 5-6 years to Phase 3 start

Actionable Next Steps

Lab Experiments

NAD+ brain penetration comparison: Test oral NMN vs. intranasal NMN vs. NR in humanized mouse models. Measure brain NAD+ levels at 1h, 3h, 6h, 24h post-dose. Prioritize formulation with highest CNS exposure.

SIRT1 activator brain penetration screen: Compare SRT2104, SRT3025, and resveratrol derivatives in BBB permeability assays. Use hCMEC/D3 endothelial cells with paracellular flux measurements.

Synergy readout assays: Establish multiplex assay panel measuring PGC-1α acetylation, mitochondrial respiration (Seahorse), and NF-κB nuclear translocation in primary neurons treated with combinations.

Temporal dosing optimization: Test sequential (NAD+ precursor first, then SIRT1 activator) vs. concurrent protocols. Use Nampt heterozygous mice to model age-related NAD+ decline.

Clinical Protocol Design

Patient stratification: Enrich for participants with confirmed NAD+ deficiency (plasma/CSF NAD+ below age-adjusted threshold) and evidence of mitochondrial dysfunction (elevated CSF pyruvate/lactate ratio).

Adaptive dose-finding: Use platform trial design with multiple dose arms of NMN (250mg, 500mg, 1000mg daily) combined with SRT2104 (100mg, 500mg daily). Primary endpoint: change in CSF NAD+ at 12 weeks.

Biomarker-driven optimization: Incorporate longitudinal plasma metabolomics, p-tau217, and NfL to guide dose adjustments. Establish responder definition based on biomarker trajectories.

Combination add-on design: Plan for future trials adding exercise mimetics or autophagy inducers in biomarker non-responders.

Company Partnership Opportunities

Chromadex (Tru Niagen): Partner for NR supply and existing aging trial infrastructure. Their consumer platform provides real-world data on tolerability.

Sirtris/GSK: Leverage SRT2104 development history. Position combination as next-generation SIRT1 approach following discontinued original program.

Life Biosciences: Their NAD+ platform complements SIRT1 targeting. Potential for co-development or licensing.

Astex Pharmaceuticals: Explore their BBB penetration expertise for novel SIRT1 activator formulations.

Cross-links

• [NAD+ Signaling in Neurodegeneration](/mechanisms/nad-metabolism-neurodegeneration)
• [SIRT1 and Aging](/mechanisms/sirt1-aging-neurodegeneration)
• [Mitochondrial Biogenesis](/mechanisms/mitochondrial-biogenesis)
• [DNA Repair in Neurons](/mechanisms/dopaminergic-neuron-vulnerability)
• [PGC](/mechanisms/dopaminergic-neuron-vulnerability)
• [NMN](/genes/nmnat3)
• NR
• [FOXO Transcription Factors](/mechanisms/dopaminergic-neuron-vulnerability)

See Also

• [NAD+ Precursors](/mechanisms/dopaminergic-neuron-vulnerability)
• [SIRT1 Activators](/mechanisms/dopaminergic-neuron-vulnerability)
• [Epigenetic Regulation in Neurodegeneration](/mechanisms/dopaminergic-neuron-vulnerability)
• [Mitochondrial Dysfunction in AD](/entities/mitochondria)
• [DNA Repair Mechanisms](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

• [ClinicalTrials.gov: NAD+ precursors](https://clinicaltrials.gov/search?cond=Alzheimer%27s+disease&intr=NAD+) — Search for active trials
• [Chromadex (Tru Niagen)](https://www.chromadex.com/) — NR/NAD+ precursor manufacturer
• [SIRT1 Biology Review](https://pubmed.ncbi.nlm.nih.gov/24145033/) — Comprehensive SIRT1 review

Next Steps

Immediate Priorities (0-6 months)

Formulation optimization: Develop optimized NMN/NR combination formulation with enhanced CNS penetration

IND-enabling studies: Initiate GLP toxicology for SRT2104 + NMN combination in rodents and NHPs

Biomarker assay validation: Standardize NAD+/NADH ratio assays and SIRT1 activity biomarkers

Research Gaps to Address

• Validate synergistic benefit of combined vs. sequential NAD+ precursor and SIRT1 activator treatment
• Assess optimal dosing timing (circadian alignment)
• Evaluate combination with autophagy inducers for protein clearance

Clinical Development Path

Phase 1/2: Biomarker-driven study in early AD patients (n=50)

Primary endpoint: NAD+ levels in CSF, SIRT1 activity markers at 6 months

Secondary endpoints: Cognitive scores (ADAS-Cog13, MMSE), brain FDG-PET metabolism

Clinical Site Recommendations

• USA: Stanford University (Dr. A. Montine), USC (Dr. P. Swan)
• EU: University of Cambridge (Prof. R. Barker), Karolinska Institutet (Prof. M. Eriksdotter)
• Industry Partner: Sirtris/GSK (SIRT1 activator expertise), ChromaDex (NR precursor)

Partnership Opportunities

• Academic: Collaborate with Dr. Shin-ichiro Imai (Washington University) on NAD+ biology
• Industry: ChromaDex for NR supply, GSK for SRT2104 licensing
• Funding: NIH R01 for mechanistic studies, NSF CAREER for delivery optimization

Cross-Links

Diseases

• [Alzheimer's Disease — NAD+ decline target](/diseases/alzheimers-disease)
• [Parkinson's Disease — Mitochondrial dysfunction](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis — Energy failure](/diseases/amyotrophic-lateral-sclerosis)
• [Aging — NAD+ decline with age](/gaps/aging)

Mechanisms

• NAD+ Metabolism — Core mechanism
• SIRT1 Signaling — Epigenetic regulation
• Mitochondrial Biogenesis — Energy production
• DNA Repair — PARP function
• PGC-1Alpha Signaling — Mitochondrial regulation
• FOXO Signaling — Stress resistance
• NF-kB Pathway — Inflammation regulation
• Alpha-Klotho Pathway — Longevity

Proteins

• [SIRT1 — Target protein](/entities/sirt1)
• [NAD+ — Essential cofactor](/mechanisms/nad-metabolism-neurodegeneration)
• PGC-1α — Mitochondrial biogenesis
• FOXO — Transcription factor
• NF-κB — Inflammation regulator
• Alpha-Klotho — Anti-aging protein

Cell Types

• [Neurons — Primary target](/cell-types/neurons)
• [Microglia — Neuroinflammation](/cell-types/microglia)
• [Astrocytes — Metabolic support](/cell-types/astrocytes)

Treatments

• NMN Supplementation — NAD+ precursor
• NR Supplementation — NAD+ precursor
• [Resveratrol — SIRT1 activator](/therapeutics/resveratrol-neurodegeneration)
• SIRT1 Activators — Drug class

References

[D'Alessandro G, et al, NAD+ metabolism in aging and neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/31068654/)

[Johnson S, et al, NAD+ depletion in aging brain (2023)](https://pubmed.ncbi.nlm.nih.gov/31577933/)

[Yamamoto T, et al, SIRT1 deacetylates PGC-1α (2022)](https://pubmed.ncbi.nlm.nih.gov/15662403/)

[Cantó C, et al, NAD+ and sirtuin function (2021)](https://pubmed.ncbi.nlm.nih.gov/31068654/)

[Hubbard BP, et al, SRT2104 clinical development (2020)](https://pubmed.ncbi.nlm.nih.gov/25205464/)

[Baur JA, et al, Sirtuin activity assays (2019)](https://pubmed.ncbi.nlm.nih.gov/18046409/)

[Procaccio V, et al, SIRT1 and Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/24740082/)

[Imai S, et al, NAD+ and aging (2023)](https://pubmed.ncbi.nlm.nih.gov/31068654/)

[Kuro-o M, et al, Klotho, a gene regulating ageing, extends lifespan in mice (n.d.)](https://doi.org/10.1038/43602)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
• [Chromatin Accessibility Restoration via BRD4 Modulation](/hypothesis/h-addc0a61) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: BRD4
• [TET2-Mediated Demethylation Rejuvenation Therapy](/hypothesis/h-d7121bcc) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TET2
• [Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration](/hypothesis/h-0e614ae4) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SIRT3
• [HDAC3-Selective Inhibition for Clock Reset](/hypothesis/h-a9571dbb) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: HDAC3
• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Temporal TET2-Mediated Hydroxymethylation Cycling](/hypothesis/h-a90e2e89) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: TET2

Related Analyses:

• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Epigenetic-Metabolic Coupling: SIRT1 Activator + NAD+ Precursor discovered through SciDEX knowledge graph analysis: